Skip to Content

'
Arlene O. Siefker-Radtke, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Genitourinary (GU) Medical Oncology, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX
Clinical Co-Leader, Bladder SPORE Executive Committee, Houston, TX

Office Address

The University of Texas M. D. Anderson Cancer Center
1155 Pressler
Unit 1374
Unit Number: Unit 1374
Houston, TX 77030
Room Number: CPB7.3506
Email: asiefker@mdanderson.org

Education & Training

Degree-Granting Education

1996 The Johns Hopkins University School of Medicine, Baltimore, MD, MD, Medicine
1992 Michigan State University, East Lansing, MI, BS, Biochemistry

Postgraduate Training

7/1999-6/2002 Clinical Fellowship, Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, Robert Wolff, M.D.
1/1996-1/1999 Clinical Residency, Internal Medicine, New England Medical Center Hospital, Boston, MA

Board Certifications

11/2002 Medical Oncology
8/1999 Internal Medicine

Experience/Service

Administrative Appointments/Responsibilities

Committee Chair, Department of Genitourinary (GU) Medical Oncology - Research, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center Clinical Research Committee, Houston, TX, 2006-present
Disease Site Liaison to the International Center, International Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/2005-present

Institutional Committee Activities

Representative, Faculty Senate, 9/2008-8/2011
Member, Institutional Review Board - IRB, 2006-present
Member, JCAHO Physician Key Contacts Committee, 1/2004-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C. miR-200 expression regulated epithelial to mesenchymal transition in bladder cancer cells and reverses resistance to EGFR therapy. Clin Cancer Res. In Press.
2. Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF, Siefker-Radtke A, Pisters LL, Swanson DA, Dinney CP, Kamat AM. Outcome of patients With bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 73(1). e-Pub 10/2008. PMCID: PMC2674246.
3. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 180(3):867-72; discussion 872, 9/2008. e-Pub 7/2008. PMID: 18635226.
4. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 14(5):1478-86, 3/2008. PMID: 18316572.
5. Siefker-Radtke, AO. Metastatic squamous cell carcinoma of the urachus: Review. Clinical Advances in Hematology & Oncology 5(11):889; 919, 11/2007.
6. Kassouf W, Spiess PE, Siefker-Radtke A, Swanson D, Grossman HB, Kamat AM, Munsell MF, Guo CC, Czerniak BA, Dinney CP. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer 110(4):764-9, 8/2007. PMID: 17614317.
7. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110(1):62-7, 7/2007. PMID: 17542024.
8. Siefker-Radtke AO. Urachal carcinoma:surgical and chemotherapeutic options. Expert Rev Anticancer Ther 6(12):1715-21, 12/2006.
9. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 107(9):2254-61, 11/2006. PMID: 17029276.
10. Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer 107(3):497-505, 8/2006. PMID: 16795067.
11. Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, Grossman HB, Dinney CP. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson cancer center experience. J Urology 175(6):2058-62, 6/2006. PMID: 16697803.
12. Siefker-Radtke AO. Systemic chemotherapy options for metastatic bladder cancer. Expert Rev Anticancer Ther 6(6):877-885, 6/2006.
13. Abrahams NA, Moran C, Reyes AO, Siefker-Radtke A, Ayala AG. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology 46(1):57-63, 1/2005. PMID: 15656887.
14. Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, Grossman HB, Swanson DA, Millikan RE. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urology 172(2):481-4, 8/2004. PMID: 15247709.
15. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B. Focus on bladder cancer. Cancer Cell 6(2):111-6, 8/2004. PMID: 15324694.
16. Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, Millikan RE. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 171(1):145-8, 1/2004. PMID: 14665863.
17. Millikan R, Siefker-Radtke A, Grossman HB. Neoadjuvant chemotherapy for bladder cancer. Urol Oncol 21(6):464-7, 11/2003. PMID: 14693274.
18. Sweeney P, Millikan R, Donat M, Wood C, Siefker Radtke AO, Pettway C, Grossman HB, Dinney C, Swanson D, Pisters L. Is there a role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urology 169(6):2113-7, 6/2003. PMID: 12771730.
19. Siefker-Radtke AO, Gee J, Shen Y, Wen S, Daliani D, Millikan RE, Pisters LL. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urology 169(4):1295-8, 4/2003. PMID: 12629346.
20. Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF, Jr, Smith TL, Williams D, Logothetis CJ. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 20(5):1361-7, 3/2002. PMID: 11870180.
21. Hsi LC, Tsai AL, Kulmacz RJ, English DG, Siefker AO, Otto JC, Smith WL. Trp387 and the putative leucine zippers of PGH synthases-1 and -2. J Lipid Mediators 6(1-3):131-138, 3/1993. PMID: 8357979.

Grant & Contract Support

Title: Targeting the erbB family in bladder cancer.
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: David McConkey
Duration: 7/1/2008 - 6/30/2013
 
Title: TRAIL receptor-based combination therapy for androgen-independent prostate cancer
Funding Source: Department of Defense (DOD)
Role: Co-Investigator
Principal Investigator: David McConkey
Duration: 2008 - 2011
 
Title: SPORE in Genitourinary Cancer
Funding Source: NIH/NCI
Role: Clinical Co-Leader
Principal Investigator: Colin Dinney
Duration: 9/25/2001 - 8/31/2011
 
Title: TRAIL Receptor-Based Combination Therapy for Androgen-Independent Prostate Cancer
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Co-Investigator

Last updated: 9/16/2009